Clinical Manual for Diagnosis, Prevention and Treatment of Cardiovascular Complications of Cancer Therapy. Part I

Clinical Manual for Diagnosis, Prevention and Treatment of Cardiovascular Complications of Cancer Therapy. Part I

Advances in treatment have led to improved survival of patients with cancer but have also resulted in untoward side effects associated with treatment. Cardiovascular diseases are one of the most frequent of these side effects. Myocardial dysfunction and heart failure, myocardial ischaemia, arrhythmi...

Full description

Bibliographic Details
Main Authors:	Chazova I.Ye., Tyulyandin S.A., Vitsenia M.V.
Format:	Article
Language:	Russian
Published:	IP Morozov P.V. 2017-09-01
Series:	Системные гипертензии
Subjects:	cardiotoxicity chemotherapy anthracyclines trastuzumab left ventricular dysfunction heart failure diagnosis prevention treatment
Online Access:	http://syst-hypertension.ru/en/archive/2017/vol-14-3-2017/clinical-manual-for-diagnosis-prevention-treatment-of-cardiovascular-complications-of-cancer-the_1811/

Similar Items

Clinical Manual for Diagnosis, Prevention and Treatment of Cardiovascular Complications of Cancer Therapy. Part I
by: I Ye Chazova, et al.
Published: (2017-12-01)

Clinical manual for diagnosis, prevention and treatment of cardiovascular complications of cancer therapy. Parts VI–VII
by: Chazova I.Ye., et al.
Published: (2018-02-01)

Clinical Manual for Diagnosis, Prevention and Treatment of Cardiovascular Complications of Cancer Therapy. Parts II–V
by: Chazova I.Ye., et al.
Published: (2017-11-01)

Left Ventricular Regional Wall Motion Abnormality is a Strong Predictor of Cardiotoxicity in Breast Cancer Patients Undergoing Chemotherapy
by: Márcio Vinícius Lins de Barros, et al.
Published: (2018-12-01)

Cardiovascular toxicities from systemic breast cancer therapy
by: Shuang eGuo, et al.
Published: (2014-12-01)

POSSIBILITIES OF IVABRADINE, A SELECTIVE INHIBITOR OF ION F-CHANNELS OF SINUS NODE, IN PREVENTION OF ANTHRACYCLINE CARDIOTOXICITY IN PATIENTS WITH BREAST CANCER
by: Yu. V. Vasyuk, et al.
Published: (2017-05-01)

Cardioprotection From Cardiotoxicity
by: Guilherme H. Oliveira, MD, MBA
Published: (2019-09-01)

Clinical manual for diagnosis, prevention and treatment of cardiovascular complications of cancer therapy. Parts VI-VII
by: I Ye Chazova, et al.
Published: (2018-03-01)

Cardio-Оncology – New Challenge in Clinical Practice
by: Sladjana Popović, Srdjan Popović, Nikolina Dukić, Jelena Vladičić-Mašić, Olivera Čančar
Published: (2020-06-01)

The cardiovascular system in patients with anthracycline cardiomiopathy
by: Alexandr T. Teplyakov, et al.
Published: (2017-10-01)

Strategies to Prevent Cardiovascular Toxicity in Breast Cancer: Is It Ready for Primetime?
by: Robin Kikuchi, et al.
Published: (2020-03-01)

Cardiotoxicity after Additional Administration of Pertuzumab following Long-Term Trastuzumab: Report of 2 Cases
by: Mayuko Ito, et al.
Published: (2021-02-01)

Statin Use Can Attenuate the Decline in Left Ventricular Ejection Fraction and the Incidence of Cardiomyopathy in Cardiotoxic Chemotherapy Recipients: A Systematic Review and Meta-Analysis
by: Jean Kim, et al.
Published: (2021-08-01)

Association of Genetic Variants at TRPC6 With Chemotherapy-Related Heart Failure
by: Nadine Norton, et al.
Published: (2020-08-01)

Cancer Therapy-Related Cardiovascular Complications in Clinical Practice: Current Perspectives
by: Michał Bohdan, et al.
Published: (2021-04-01)

Efficacy and safety of carvedilol in combination with bronchodilators in patients with CHF of ischemic origin and COPD.
by: Vladimir V. Evdokimov, et al.
Published: (2019-04-01)

Cardiooncology. Basic principles of prevention and treatment of cardiotoxicity in cancer patients
by: Ekaterina V. Plokhova, et al.
Published: (2019-04-01)

Clinical Manual for Diagnosis, Prevention and Treatment of Cardiovascular Complications of Cancer Therapy. Parts II-V
by: I Ye Chazova, et al.
Published: (2017-12-01)

Cardiotoxicity of cancer therapeutics: current issues in screening, prevention and therapy
by: Richard Joseph Sheppard, et al.
Published: (2013-03-01)

The diagnosis of anthracycline-induced cardiac damage and heart failure
by: Jarosław Dudka, et al.
Published: (2009-05-01)

Management strategies and clinical outcomes in breast cancer patients who develop left ventricular dysfunction during trastuzumab therapy
by: Ren Jie Robert Yao, et al.
Published: (2021-03-01)

microRNA-377 Signaling Modulates Anticancer Drug-Induced Cardiotoxicity in Mice
by: John Henderson, et al.
Published: (2021-08-01)

CARDIOVASCULAR COMPLICATIONS CAUSED BY CHEMOTHERAPY AND TARGETED AGENTS
by: L. V. Bolotina, et al.
Published: (2016-01-01)

The effect of anthracyclines in minimal doses on cardiac function of children under chemotherapy
by: Shiva Rahimi Dehgolan, et al.
Published: (2014-07-01)

Physical activity during and after breast cancer therapy and associations of baseline physical activity with changes in cardiac function by echocardiography
by: Jenica N. Upshaw, et al.
Published: (2020-09-01)

Magnetic Resonance Imaging to Detect Cardiovascular Effects of Cancer Therapy
by: Iwan Harries, MBBCh, et al.
Published: (2020-06-01)

The Evolving Design of NIH-Funded Cardio-Oncology Studies to Address Cancer Treatment-Related Cardiovascular Toxicity
by: Lori M. Minasian, MD, et al.
Published: (2019-09-01)

Anthracycline-associated cardiotoxicity in adults: systematic review on the cardioprotective role of beta-blockers
by: Roberto Ramos Barbosa, et al.

Left Ventricular Diastolic Function Following Anthracycline-Based Chemotherapy in Patients with Breast Cancer without Previous Cardiac Disease—A Meta-Analysis
by: Raluca I. Mincu, et al.
Published: (2021-08-01)

Protection against Doxorubicin-Induced Cardiac Dysfunction Is Not Maintained Following Prolonged Autophagy Inhibition
by: Ryan N. Montalvo, et al.
Published: (2020-10-01)

Is it possible to prevent chemotherapy-induced heart failure with cardiovascular drugs - the review of the current clinical evidence
by: Korzeniowska K, et al.
Published: (2019-09-01)

Methods of diagnosis in cardio-oncology
by: E. V. Plokhova, et al.
Published: (2018-12-01)

An increase in myocardial 18-fluorodeoxyglucose uptake is associated with left ventricular ejection fraction decline in Hodgkin lymphoma patients treated with anthracycline
by: Matteo Sarocchi, et al.
Published: (2018-10-01)

Early Detection and Monitoring of Cancer Chemotherapy-Related Left Ventricular Dysfunction by Imaging Methods
by: Mario Luiz Ribeiro, et al.
Published: (2019-02-01)

Empagliflozin prevents doxorubicin-induced myocardial dysfunction
by: Jolanda Sabatino, et al.
Published: (2020-05-01)

Protective Effects of ω-3 PUFA in Anthracycline-Induced Cardiotoxicity: A Critical Review
by: Simona Serini, et al.
Published: (2017-12-01)

Антрациклины в лечении солидных опухолей у детей
by: Владимир Евгеньевич Белецкий
Published: (2015-04-01)

Risk Factors for Anthracycline-Induced Cardiotoxicity
by: Shuo Qiu, et al.
Published: (2021-09-01)

MODERN VIEW ON CARDIOTOXICITY OF CHEMOTHERAPEUTICS IN ONCOLOGY INCLUDING ANTHRACYCLINES
by: G. E. Gendlin, et al.
Published: (2017-03-01)

Efficacy and cardiac safety of the concurrent use of trastuzumab and anthracycline-based neoadjuvant chemotherapy for HER2-positive breast cancer: a systematic review and meta-analysis
by: Wu Y, et al.
Published: (2018-09-01)